Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience

IF 2.3 3区医学 Q2 BEHAVIORAL SCIENCES

Epilepsy & Behavior Pub Date : 2025-10-22 DOI:10.1016/j.yebeh.2025.110718

Xueying Wang , Lin Yang , Shaoping Huang , Dan Li , Yu Liu , Yingying Guo , Na Sun , Gaobo Ye , Yonghui Dang

{"title":"Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience","authors":"Xueying Wang , Lin Yang , Shaoping Huang , Dan Li , Yu Liu , Yingying Guo , Na Sun , Gaobo Ye , Yonghui Dang","doi":"10.1016/j.yebeh.2025.110718","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the clinical efficacy and safety of the combination of lacosamide (LCM) and oxcarbazepine (OXC) in children with focal epilepsy, either as a dual therapy or in combination with other anti-seizure medications.</div></div><div><h3>Methods</h3><div>We collected clinical data retrospectively from pediatric epilepsy patients treated with both LCM and OXC for at least 6 months at the Department of Pediatrics, Second Affiliated Hospital of Xi’an Jiaotong University, between January 2021 and July 2023. Efficacy and adverse events were investigated.</div></div><div><h3>Results</h3><div>Collectively, 69 pediatric patients were included, with ages ranging from 1 to 18 years. The age at onset of epilepsy varied from 15 days to 14.8 years. Disease duration ranged from 1 month to 14 years. All pediatric patients exhibited focal seizures, with the maximum number of concurrent combined medications being six. The maintenance dose of LCM for all pediatric patients was between 3.8 and 10 mg/kg, while that of OXC was between 15 and 40 mg/kg. Over half of the patients showed a greater than 50 % reduction in seizure frequency during long-term follow-up. The most frequently reported adverse reactions included hyponatremia, headache, dizziness, somnolence, and nausea; no patients experienced rash as an adverse reaction.</div></div><div><h3>Conclusion</h3><div>The combination of LCM and OXC has shown promising efficacy and tolerability in pediatric patients with focal epilepsy. This therapeutic combination is a worthwhile option to consider for patients with focal epilepsy, especially those with underlying structural abnormalities.</div></div>","PeriodicalId":11847,"journal":{"name":"Epilepsy & Behavior","volume":"173 ","pages":"Article 110718"},"PeriodicalIF":2.3000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsy & Behavior","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525505025004585","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To investigate the clinical efficacy and safety of the combination of lacosamide (LCM) and oxcarbazepine (OXC) in children with focal epilepsy, either as a dual therapy or in combination with other anti-seizure medications.

Methods

We collected clinical data retrospectively from pediatric epilepsy patients treated with both LCM and OXC for at least 6 months at the Department of Pediatrics, Second Affiliated Hospital of Xi’an Jiaotong University, between January 2021 and July 2023. Efficacy and adverse events were investigated.

Results

Collectively, 69 pediatric patients were included, with ages ranging from 1 to 18 years. The age at onset of epilepsy varied from 15 days to 14.8 years. Disease duration ranged from 1 month to 14 years. All pediatric patients exhibited focal seizures, with the maximum number of concurrent combined medications being six. The maintenance dose of LCM for all pediatric patients was between 3.8 and 10 mg/kg, while that of OXC was between 15 and 40 mg/kg. Over half of the patients showed a greater than 50 % reduction in seizure frequency during long-term follow-up. The most frequently reported adverse reactions included hyponatremia, headache, dizziness, somnolence, and nausea; no patients experienced rash as an adverse reaction.

Conclusion

The combination of LCM and OXC has shown promising efficacy and tolerability in pediatric patients with focal epilepsy. This therapeutic combination is a worthwhile option to consider for patients with focal epilepsy, especially those with underlying structural abnormalities.

查看原文本刊更多论文

拉科沙胺和奥卡西平长期联合治疗小儿局灶性癫痫的疗效和安全性：真实世界的临床经验。

目的：探讨拉科沙胺（LCM）与奥卡西平（OXC）联用治疗局灶性癫痫患儿的临床疗效和安全性，无论是单用还是联用其他抗癫痫药物。方法：回顾性收集2021年1月至2023年7月在西安交通大学第二附属医院儿科同时使用LCM和OXC治疗至少6个月的儿童癫痫患者的临床资料。观察疗效及不良反应。结果：共纳入69例儿童患者，年龄在1 - 18岁之间。癫痫发作的年龄从15天到14.8岁不等。病程从1个月到14年不等。所有儿童患者均表现出局灶性癫痫发作，同时联合用药的最多次数为6次。所有儿童患者的LCM维持剂量在3.8 ~ 10mg /kg之间，OXC维持剂量在15 ~ 40mg /kg之间。在长期随访中，超过一半的患者癫痫发作频率降低50%以上。最常见的不良反应包括低钠血症、头痛、头晕、嗜睡和恶心；没有患者出现皮疹作为不良反应。结论：LCM联合OXC治疗小儿局灶性癫痫具有良好的疗效和耐受性。对于局灶性癫痫患者，特别是那些有潜在结构异常的患者，这种治疗组合是一个值得考虑的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epilepsy & Behavior 医学-行为科学

CiteScore

5.40

自引率

15.40%

发文量

385

审稿时长

43 days

期刊介绍： Epilepsy & Behavior is the fastest-growing international journal uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy. Epilepsy & Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging. From September 2012 Epilepsy & Behavior stopped accepting Case Reports for publication in the journal. From this date authors who submit to Epilepsy & Behavior will be offered a transfer or asked to resubmit their Case Reports to its new sister journal, Epilepsy & Behavior Case Reports.